Adalta Ltd. · ASX:1AD
Adalta — Investor Presentation (August 2025)
27 slides from Adalta's investor presentation, Aug 19, 2025
Slide 1: Commercialising Life Saving Cellular Immunotherapies
COMMERCIALISING LIFE SAVING CELLULAR IMMUNOTHERAPIES “EAST TO WEST” ADALTA LIMITED (ASX:1AD) | INVESTOR PRESENTATION | AUGUST 2025 AdAlta Limited (ASX:1AD) | Investor Presentation | August 2025 | 1
Slide 2: Important Notice & Disclaimer
IMPORTANT NOTICE & DISCLAIMER Investment in AdAlta is subject to investment risk, including possible loss of income and capital invested. AdAlta does not guarantee any particular rate of return or performance, nor do they guarantee the repayment of capital. This presentation is not an offer or invit
Slide 3: AdAlta: Next Generation Cell & Protein Therapeutics
ADALTA: NEXT GENERATION CELL & PROTEIN THERAPEUTICS “East to West” cellular immunotherapy strategy for growth: AdCella In-license next generation clinical stage assets from Asia, establish Western manufacturing and generate clinical data for on-licensing AdAlta is a clinical stage biotech: Leverages
Slide 4: "East to West" Strategy Central to AdAlta's Growth
“EAST TO WEST” STRATEGY CENTRAL TO ADALTA’S GROWTH AdCella Pty Ltd, an AdAlta company AdAlta Limited (ASX:1AD) | Investor Presentation | August 2025 | 44
Slide 5: Trend #1 Powering Our Strategy: CAR-T Revolution
TREND #1 POWERING OUR STRATEGY: CAR-T REVOLUTION 7 CAR-T products approved in US since 20171 Complete response rates in relapsed and refractory Turbo-charging 51-83% patients with no other options2 patient’s immune cells to “see” and “kill” cancer Living drug, single CAR-T 2 Solid cancer T cell ther
Slide 6: Trend #2 Powering Our Strategy: Rise of China Biotech
TREND #2 POWERING OUR STRATEGY: RISE OF CHINA BIOTECH China biotech is now driving global … creating significant pool of highly … but still facing barriers to reach biopharmaceutical innovation …2 innovative CAR-T products … Western patients5 Big pharma licensing deals now 30% involving a China biot
Slide 7: Our Solution: Becoming a Valuation Multiplier for Asian Partners
OUR SOLUTION: BECOMING A VALUATION MULTIPLIER FOR ASIAN PARTNERS 3 1. Low cost in-license of 3 market leading assets 1 from Asia (“East”): By financing to next 3. High value out-licensing to inflection point AdAlta realise substantial value acquires a share of the creation: asset at exit Establish g
Slide 8: Business System
BUSINESS SYSTEM Low cost asset acquisition, efficient value-adding development, high value exit AdAlta leverages third party financing to create value for shareholders – indicative only Larger biopharma companies Ownership – 1st financing conduct late-stage clinical 4. Efficient trials and bring to
Slide 9: Asset #1: First-in-Class Armoured X-CAR-T
ASSET #1: FIRST-IN-CLASS ARMOURED X-CAR-T Product #1 Advanced, solid cancer Armoured-X-CAR-T patient: sustained response What is the Anti-PD1 secreting CAR-T manufactured using 30h virus to armored-CAR-T product? free process Which cancers Lung, mesothelioma, ovarian, cervical, pancreatic, could it
Slide 10: Asset #2: First-in-Class Y-CAR-T
ASSET #2: FIRST-IN-CLASS Y-CAR-T Product #2 Pancreatic tumor B4T2-001 cleared bypancreatic CAR-T Y-CAR-T in re-challenge model tumor re-challenge • We conducted a tumor re-challenge study in which Y-CAR-T mice were re-engraftment with tumor cells after having experienced a complete response to a Unt
Slide 11: "East to West" Strategy Summary
“EAST TO WEST” STRATEGY SUMMARY Substantial value inflection potential by bringing “Eastern” cellular AdCella has clear immunotherapy innovations to “Western” regulated markets aspirational growth targets for its Exclusive focus on T cell therapies for solid cancers targets less “East to West” strat
Slide 12: AD-214: A New Approach to Fibrosis Available for Partnering
AD-214: A NEW APPROACH TO FIBROSIS AVAILABLE FOR PARTNERING AdAlta Limited (ASX:1AD) | Investor Presentation | 12 August 2025 | 12
Slide 13: Monetising Fibrosis Disease Drug Candidate AD-214
MONETISING FIBROSIS DISEASE DRUG CANDIDATE AD-214 Investment to date has built strong value proposition Key Priority: Seek out-licensing or third-party investment to unlock next level of value First in class molecule targeting established mode ✓ Competitively positioned as only antibody-like Advisor
Slide 14: Underserved and Large Fibrotic Disease Market
UNDERSERVED AND LARGE FIBROTIC DISEASE MARKET IPF market is underserved today Many other fibrosis market opportunities2 • Poor efficacy: Existing therapies slow but do not halt progression and do not significantly extend life expectancy • Side effects: Their side effects result in 30-50% of patients
Slide 15: Pharma Companies Value IPF/Fibrosis Assets
PHARMA COMPANIES VALUE IPF/FIBROSIS ASSETS Upfront payment to Contingent Clinical Phase at Date Licensor/target Licensee/acquirer Transaction licensor milestones transaction Aug-22 License US$100m US$600m 2 complete Apr-20 Acquisition US$45m Not disclosed 2a complete Nov-19 Acquisition US$390m US$1,
Slide 16: WD-34 i-body: A Potential Breakthrough in Malaria Available for Partnering
WD-34 I-BODY: A POTENTIAL BREAKTHROUGH IN MALARIA AVAILABLE FOR PARTNERING AdAlta Limited (ASX:1AD) | Investor Presentation | 16 August 2025 | 16
Slide 17: World First Pan-Species High Potency Anti-Malarial
WORLD FIRST PAN-SPECIES HIGH POTENCY ANTI-MALARIAL WD-34 i-body has potential to transform malaria treatment Strategy: seeking non-dilutive and commercial ✓ 247 million cases, 619,000 deaths in 20211 partners to advance outside AdAlta Malaria remains a ✓ Re-emerging in US and EU2 global killer Activ
Slide 18: Corporate Information
CORPORATE INFORMATION AdAlta Limited (ASX:1AD) | Investor Presentation | 18 August 2025 | 18
Slide 19: Corporate Snapshot
CORPORATE SNAPSHOT AdAlta Limited Specialist in next-generation cell and protein therapeutics for fatal diseases Code ASX:1AD Market Capitalisation $3.0m Exclusive position on three "East-to-West" cell Enterprise Value $1.7m therapy assets, with team and execution Cash (30 June 2025) $1.3m network i
Slide 20: Experienced Team with Global Reach
EXPERIENCED TEAM WITH GLOBAL REACH Board Executive “East-to-West” Strategy AD-214: Fibrosis Paul MacLeman, DVM Angus Tester, PhD Kevin Lynch TBA - engaged Chair Senior Director Operations Consultant CMO Consultant CMO Prof Andrew Wilks Joseph Tyler VC Advisor Consultant CMC Expert Tim Oldham, PhD Ja
Slide 21: Transaction-Based Growth Strategy Is Being Delivered
TRANSACTION-BASED GROWTH STRATEGY IS BEING DELIVERED “East to West” cellular Exclusive position on first two Experienced team and accessible immunotherapy growth strategy assets for the “East to West” clinical global network ready to execute a positioned for growth leveraging Asia pipeline to create
Slide 22: For More Information Please Contact
FOR MORE INFORMATION PLEASE CONTACT: TIM OLDHAM CEO & MANAGING DIRECTOR +61 403 446 665 T.OLDHAM@ADALTA.COM.AU IR@ADALTA.COM.AU WWW.ADALTA.COM.AU AdAlta Limited (ASX:1AD) | Investor Presentation | August 2025 | 22
Slide 23: The Market Opportunity
THE MARKET OPPORTUNITY T cell solid cancer therapy: the next frontier for cellular immunotherapy In 2024, FDA approved two What is T-cell therapy? 7 FDA-approved CAR-T T cell therapies for solid therapies since 2017 cancer (melanoma, Involves re-engineering and transformed blood cancer sarcoma), ope
Slide 24: Value at Exit: Phase I CAR-T Licensing Transactions
VALUE AT EXIT: PHASE I CAR-T LICENSING TRANSACTIONS Total Upfront Date Drug(s) Licensor Licensee Deal stage Lead indications value (US$m) (US$m) MAGE-A4 targeting TCR T Phase 2 May-24 Head & neck cancer 665 85 cell therapy (ongoing; global) DLL3 targeting autologous Phase 1 Nov-23 SCLC, LCNEC 1,110
Slide 25: Accessing Quality Assets from Asia
ACCESSING QUALITY ASSETS FROM ASIA Quality Asia cellular Flow of innovation from Asia to the West is hampered by: lack of capital in Asia, lack of Western immunotherapy pipeline, experience and networks, opportunity cost for large biopharma to conduct due diligence, difficulty barriers to reach West
Slide 26: Leveraging AdCella's Competitive Advantages
LEVERAGING ADCELLA’S COMPETITIVE ADVANTAGES Process: asset sourcing discipline Value: capital-light, risk managed • T cell therapies for solid cancers • AdAlta managed; JV/asset financed • Differentiated, multi-functional • Defined investment in clinically product design derisked asset • Clinical da
Slide 27: Progress and Potential
PROGRESS AND POTENTIAL Asset acquisition stream – exclusive access secured Australian clinical • Technical and on-site diligence, development planning complete We are here trial data facilitates • On track for first asset license Q3 2025 pivotal studies, today • Discussions opening with clinical tri